Seesaw of matrix metalloproteinases (MMPs)

Journal of Cancer Research and Therapeutics

Volumn 12, Issue 1, 2016, Pages 28-35

  Kapoor, Charu ^a   Vaidya, Sharad ^a,b   Wadhwan, Vijay ^a,c   Hitesh, ^a,d   Kaur, Geetpriya ^a,e   Pathak, Aparna ^a,e  

^a Bhojia Dental College & Hospital   (India)

^b Himachal Dental College   (India)

^c SUBHARTI DENTAL COLLEGE   (India)

^d MANAV RACHNA INTERNATIONAL INSTITUTE OF RESEARCH AND STUDIES   (India)

^e Paradise Diagnostics   (India)

Author keywords

Disease; inflammation; matrix metalloproteinase inhibitors; tissue remodeling; wound healing

Indexed keywords

MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR;

ANGIOGENESIS; CLASSIFICATION; DRUG TARGETING; ENZYME STRUCTURE; HEALING; HUMAN; IMMUNE RESPONSE; INFLAMMATION; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; ORAL MUCOSAL DISEASE; REVIEW; TUMOR INVASION; CARCINOGENESIS; EXTRACELLULAR MATRIX; GENETICS; METABOLISM; NEOPLASMS; PATHOLOGY;

CARCINOGENESIS; EXTRACELLULAR MATRIX; HUMANS; MATRIX METALLOPROTEINASE INHIBITORS; MATRIX METALLOPROTEINASES; NEOPLASMS;

EID: 84966540007     PISSN: 09731482     EISSN: 19984138     Source Type: Journal    
DOI: 10.4103/0973-1482.157337     Document Type: Review

References (26)

1. Nabeshima K, Inoue T, Shimao Y, Sameshima T. Matrix metalloproteinases in tumor invasion: Role for cell migration. Pathol Int 2002;52:255-64.
2. Woessner JF Jr, Nagase H. Functions of the TIMPs. In: Matrix Metalloproteinases and TIMPs. New York, NY: Oxford University Press; 2000. p. 130-5.
3. Rydlova M, Holubec L Jr, Ludvikova M Jr, Kalfert D, Franekova J, Povysil C, et al. Biological activity and clinical implications of the matrix metalloproteinases. Anticancer Res 2008;28:1389-97.
4. Alexander CM, Hansell EJ, Behrendtsen O, Flannery ML, Kishnani NS, Hawkes SP, et al. Expression and function of matrix metalloproteinases and their inhibitors at the maternal-embryonic boundary during mouse embryo implantation. Development 1996;122:1723-36.
5. Baker AH, Edwards DR, Murphy G. Metalloproteinase inhibitors: Biological actions and therapeutic opportunities. J Cell Sci 2002;115:3719-27.
6. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: Trials and tribulations. Science 2002;295:2387-92.
7. Overall CM, Lopez-Otin C. Strategies for MMP inhibition in cancer: Innovations for the post-trial era. Nat Rev Cancer 2002;2:657-72.
8. Lockhart AC, Braun RD, Yu D, Ross JR, Dewhirst MW, Humphrey JS, et al. Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor. Clin Cancer Res 2003;9:586-93.
9. Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997;89:1260-70.
10. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-74.
11. McCawley LJ, Matrisian LM. Matrix metalloproteinases: They're not just for matrix anymore! Curr Opin Cell Biol 2001;13:534-40.
12. Korem S, Kraiem Z, Shiloni E, Yehezkel O, Sadeh O, Resnick MB. Increased expression of matrix metalloproteinase-2: A diagnostic marker but not prognostic marker of papillary thyroid carcinoma. Isr Med Assoc J 2002;4:247-51.
13. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: Biologic activity and clinical implications. J Clin Oncol 2000;18:1135-49.
14. Stetler-Stevenson WG. Matrix metalloproteinases in angiogenesis: A moving target for therapeutic intervention. J Clin Invest 1999;103:1237-41.
15. Massi D, Franchi A, Ketabchi S, Paglierani M, Pimpinelli N, Santucci M. Expression and prognostic significance of matrix metalloproteinases and their tissue inhibitors in primary neuroendocrine carcinoma of the skin. Hum Pathol 2003;34:80-8.
16. Mannello F. Natural bio-drugs as matrix metalloproteinase inhibitors: New perspectives on the horizon? Recent Pat Anticancer Drug Discov 2006;1:91-103.
17. Krüger A, Arlt MJ, Gerg M, Kopitz C, Bernardo MM, Chang M, et al. Antimetastatic activity of a novel mechanism-based gelatinase inhibitor. Cancer Res 2005;65:3523-6.
18. Rudek MA, Venitz J, Figg WD. Matrix metalloproteinase inhibitors: Do they have a place in anticancer therapy? Pharmacotherapy 2002;22:705-20.
19. Sood AK, Fletcher MS, Coffin JE, Yang M, Seftor EA, Gruman LM, et al. Functional role of matrix metalloproteinases in ovarian tumor cell plasticity. Am J Obstet Gynecol 2004;190:899-909.
20. Parks WC, Mecham RP. Matrix Metalloproteinases. San Diego, Calif: Academic Press; 1998. p. 1-14.
21. Nagel H, Laskawi R, Wahlers A, Hemmerlein B. Expression of matrix metalloproteinases MMP-2, MMP-9 and their tissue inhibitors TIMP-1,-2, and-3 in benign and malignant tumours of the salivary gland. Histopathology 2004;44:222-31.
22. Kren L, Goncharuk VN, Krenová Z, Stratil D, Hermanová M, Skrickova J, et al. Expression of matrix metalloproteinase 3,10,11 (stromelysins 1, 2 and 3) and matrix metalloproteinase 7 (matrilysin) by cancer cells in non-small cell lung neoplasms. Clinicopathologic studies. Cesk Patol 2006;42:16-9.
23. Sogawa K, Kondo K, Fujino H, Takahashi Y, Miyoshi T, Sakiyama S, et al. Increased expression of matrix metalloproteinase-2 and tissue inhibitor of metallopro-teinase-2 is correlated with poor prognostic variables in patients with thymic epithelial tumors. Cancer 2002;98:1822-9.
24. Kumamoto H, Yamauchi K, Yoshida M, Ooya K. Immunohistochemical detection of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in ameloblastomas. J Oral Pathol Med 2003;32:114-20.
25. Mitani O, Katoh M, Shigematsu H. Participation of the matrix metalloproteinase inhibitor in Thy-1 nephritis. Pathol Int 2004;54:241-50.
26. Span PN, Sweep CG, Manders P, Beex LV, Leppert D, Lindberg RL. Matrix metalloproteinase inhibitor reversion-inducing cysteine-rich protein with Kazal motifs: A prognostic marker for good clinical outcome in human breast carcinoma. Cancer 2003;97:2710-5.